This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Neurology				
Alzheimer's disease (AD); cognitive dysfunction	Serotonin (5-HT ₆) receptor (HTR ₆)	<p>A study in rats identified a 5-cyclic amine-3-arylsulfonylindazole-based HTR₆ antagonist that could help improve cognition in diseases like AD. In a rodent learning study, the HTR₆ antagonist significantly improved memory performance compared with vehicle control ($p < 0.05$). The compound also showed good brain penetrability and had a favorable pharmacokinetic profile. Next steps include improving the potency of the HTR₆ antagonist and its related compounds. At least eight companies have HTR₆ antagonists in Phase II or earlier to treat AD, cognitive dysfunction or schizophrenia.</p> <p>SciBX 3(10); doi:10.1038/scibx.2010.315 Published online March 11, 2010</p>	Patent and licensing status unavailable	<p>Haydar, S.N. <i>et al. J. Med. Chem.</i>; published online Feb. 19, 2010; doi:10.1021/jm901674f</p> <p>Contact: Simon N. Haydar, Wyeth Research, Princeton, N.J. e-mail: Haydars@wyeth.com or simonhaydar@hotmail.com</p>